Research News 2
Research News
-
Predicting Changes in the HIV Reservoir
Researchers zero in on a marker, sugar-protein Galectin-9, that might be able to target HIV persistence, the main barrier to a cure for people living with the virus.
-
A Possible New Avenue to a Cure
A study of the Geneva patient, cured of HIV via a transplant with cells susceptible to infection, opens up new possibilities of eradicating the virus.
-
Lenacapavir Looks to Revolutionize HIV Prevention
PURPOSE 2 study results show that a twice-yearly injectable HIV antiretroviral, lenacapavir, is highly effective as PrEP among MSM, transgender women and men who have sex with men, and others.
-
Researchers Identify a Novel Cell Protein that Can Control HIV Growth
Researchers have discovered a cell protein that can restrict the late phases of HIV replication as well as that of pox viruses.
-
Next-Generation PrEP
PURPOSE 1 trial results show that a twice-yearly injectable—lenacapavir for PrEP—is 100% effective at preventing HIV infection among cisgender women and girls.
-
Daily Updates from the 2024 International AIDS Conference
Daily updates of sessions at AIDS 2024 cover research on curing HIV, HIV care, and AIDS policy from amfAR and others.
-
The Second Berlin Patient
A seventh person, the second Berlin Patient, has been cured of HIV, providing new evidence that a stem cell transplant with a CCR5 gene mutation might not be the only path to a cure.
-
amfAR Greenlights New HIV Cure Studies with Grants Totaling $1.2 Million
amfAR grants totaling $1.2 million allow three researchers to test the ability of a pair of cancer drugs and broadly neutralizing antibodies to attack HIV reservoirs, the main barrier to a cure.
-
Forming HIV Reservoirs, Informing Cure Strategies
Researchers, led by amfAR grantee Dr. Edward Kankaka, gain new insight into the initial formation of HIV reservoirs, the main barrier to an HIV cure.
-
amfAR at AIDS 2024: Presentations, Meetings, and Workshops
A full listing of amfAR-related presentations and sessions at AIDS 2024
-
How One Cure Strategy May Lead to Another
With a better understanding of how stem cell transplants help reduce the HIV reservoir, researchers are closer to defining new targets for scalable cure interventions
-
Timing Is Everything
Timing of ART initiation after infection determines vulnerability of the HIV reservoir, the main barrier to a cure
-
Uganda’s Anti-Homosexuality Law Cannot Stand
amfAR criticizes Uganda Constitutional Court’s refusal to strike down its Anti-Homosexuality Act, citing HIV healthcare and human rights violations.
-
Creating a Cost-Effective Cure
Researchers design a highly potent latency reversing agent that targets the HIV reservoir, the main barrier to a cure, and boosts immune responses.
-
Rejuvenating the Field of AIDS Research
Three promising young HIV researchers—Drs. Gabriel Duette, Kalen Petersen, and Simone Richardson—have been awarded amfAR’s Mathilde Krim Fellowship in Biomedical Research.